ORYZON Genomics to present at the 2015 Alzheimer's Association International Conference
Oryzon Genomics, an epigenetics-based biotechnology company focused on developing therapeutics in oncology and neurodegenerative diseases will present this week their last results on its late preclinical Alzheimer’s drug ORY-2001 at the 2015 Alzheimer's Association International Conference in Washington DC.
The company will present this data on Wednesday 22nd at the Hall D of the Walter E. Washington Convention center with a poster entitled: Ory-2001 a Dual LSD1/MAO-B Inhibitor Prevents the Development of the Memory Deficit in Samp-8 Mice. The company is developing ORY-2001, a dual LSD1-MAOB inhibitor, as a new therapeutic approach for Alzheimer’s disease (AD). The molecule is expected to start Phase I early next year.